logo
To fight a trade war, it's nice to have friends

To fight a trade war, it's nice to have friends

Axios11-04-2025

To fight a trade war against China, most foreign policy experts would say that you need allies.
Why it matters: Over the past few months, the White House antagonized pretty much all its friends on the global stage, making it that much harder to carry out what is now a full-blown tariff battle with China.
The big picture: China is a formidable economic force, the second-largest economy in the world, with significant resources like a vast labor supply, manufacturing heft, a growing electric vehicle industry and expanding military might.
"On critical metrics, China has already outmatched the United States," write the authors of a sobering new piece in Foreign Affairs.
Zoom in: The best shot the U.S. has at holding its economic edge is in forging partnerships, Kurt Campbell and Rush Doshi write: "China possesses scale, and the United States does not — at least not by itself."
"Because its only viable path lies in coalition with others, Washington would be particularly unwise to go it alone in a complex global competition."
The intrigue: The authors, who both worked on foreign affairs in the Biden administration, wrote the piece before "Liberation Day."
But we "kind of saw that coming," Doshi, now a professor of security studies at Georgetown University and director of the China Strategy Initiative at the Council of Foreign Relations, tells Axios.
Zoom in: Such a coalition would go beyond the traditional post-Cold War frame of the U.S. playing a protector role. This would be more about forging economic partnerships.
"I'm talking about us all getting together with our allies, putting tariffs or regulatory barriers up together to protect our industries from China's massive export capacity," Doshi says.
"Ideally the U.S. would lower barriers between its allies, to put market share together so that our companies have a bigger playing field."
But right now, U.S. allies have the tariffs of Damocles hanging over their heads, says Wendy Edelberg, a senior fellow in economic studies at the Brookings Institution.
On Wednesday, President Trump announced a 90-day pause on his "reciprocal" tariffs, and it's not the kind of pause that refreshes.
"It's not like other countries know for certain that they even have a reprieve," Edelberg says.
By the numbers: U.S. tariffs on China now average 134.7%, per a calculation from the Peterson Institute for International Economics.
China's been retaliating, this morning raising tariffs on U.S. goods even more to 125%. It could end very badly, though many expect some kind of deal or postponement.
"At current tariff levels, U.S. exports to China are no longer marketable," China's tariff commission said in a statement quoted this morning in the Wall Street Journal.
"If the U.S. insists on playing the numbers game with tariffs, China will disregard it." The statement adds that China will "fight" if the U.S. persists in harming its interests.
Yes, but: "We can put America first and work with other countries at the same time," a White House official tells Axios. "The U.S. is not acting alone in acting on China's unfair trading practices."
They note many countries have initiated anti-dumping World Trade Organization investigations against China, and that "even Russia is imposing higher duties on Chinese EV cars."
For the record: "President Trump is playing chess while the Chinese are playing checkers, to the detriment of their economy and their people," says Harrison Fields, a White House spokesperson.
Flashback: The trade war with China during the first Trump administration ended with an agreement. Among other things, China said it would buy $200 billion worth of American imports.
That didn't happen. Partly, the coronavirus pandemic got in the way, but other factors were also at play.
"Today the only undisputed 'historical' aspect of that agreement is its failure," Chad Bown wrote in a 2022 piece for the Peterson Institute.
Reality check: The current Chinese economy is in a bad place. Consumer prices declined for the second month in a row, per data out Wednesday, a worrying sign deflation might be setting in. Unemployment is rising.
A trade war with its biggest foreign trading partner is only going to add to its woes.
Still, China's leaders believe their country is better able to withstand the fight, Han Lin, the Asia Group China director in Shanghai, said on BBC Business Matters on Wednesday.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Angelini Ventures Invests into €11.25 Million Seed Round for Elkedonia to Advance Neuroplastogens as Novel Therapeutics for Depression and Neuropsychiatric Disorders
Angelini Ventures Invests into €11.25 Million Seed Round for Elkedonia to Advance Neuroplastogens as Novel Therapeutics for Depression and Neuropsychiatric Disorders

Yahoo

time39 minutes ago

  • Yahoo

Angelini Ventures Invests into €11.25 Million Seed Round for Elkedonia to Advance Neuroplastogens as Novel Therapeutics for Depression and Neuropsychiatric Disorders

Rome, Italy, 11th June 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and Digital Health, announces its investment in Elkedonia SAS (Strasbourg, France), a pioneering biotech company developing a first-in-class neuroplastogen for the treatment of depression and other neuropsychiatric disorders. This €11.25 million seed round was co-led by Kurma Partners, WE Life Sciences and Bpifrance, with participation from Angelini Ventures, Argobio, Carma Fund, Capital Grand Est and Sambrinvest. The funds raised will be used to advance Elkedonia's novel neuroplastogen approach to identify and optimize drug-like small molecule inhibitors of Elk1, a novel intracellular target previously considered to be "undruggable". Elk1 plays a pivotal role in reward brain circuits and neuroplasticity. These mechanisms are often altered in conditions like depression, Post-Traumatic Stress Disorder (PTSD), and addiction, making them chronic instead of transient. Preclinical and clinical studies suggest that Elk1 inhibition offers a promising and differentiated new approach to treating treatment-resistant depression, with rapid efficacy and without the side effects of psychedelics or ketamine derivatives, such as sedation, dependence, or hallucinations. Part of the financing will be directed toward biomarker research and validation efforts, supporting a precision-based therapeutic strategy. This scientific and commercial potential was identified early by Argobio, which selected and developed Elkedonia within its venture studio. Founded in Paris and backed by leading investors including Angelini Ventures, Argobio partners with European academic institutions to transform early-stage discoveries into biotech companies, with a focus on rare diseases, neuroscience, oncology and is the first of these ventures to reach a significant financing milestone — a clear validation of Argobio's model and approach. This strong European investor syndicate reflects both the confidence of Argobio's founding investors in its model and Elkedonia's ability to attract leading life sciences investors at the seed stage. Building on this momentum, Argobio continues to expand its portfolio with the ambition to scale a repeatable model of biotech creation, driven by scientific excellence, entrepreneurial leadership and long-term investor alignment. 'We are excited to support Elkedonia's groundbreaking work in advancing neuroplastogens, which represents a potential first-in-class approach to treating depression,' said Fabrizio Calisti, Medical Director at Angelini Ventures. 'The novel nature of Elkedonia's target Elk1, previously thought to be undruggable, sets the company apart in the landscape of depression treatments, and we are proud to be part of this transformative journey. This investment reflects Angelini Ventures' commitment to supporting the exciting science coming out of European academic laboratories at the earliest stages via Argobio and subsequently providing further capital through our venture fund to accelerate the translation of cutting-edge research into therapies with the potential to transform outcomes for people with neuropsychiatric disorders.' Fabrizio Calisti, M.D., Medical Director at Angelini Ventures, will join Elkedonia's Board of Directors. 'I am thrilled to welcome our founding seed investors and thank my colleagues at Argobio for their support in creating Elkedonia. The novelty of our neuroplastogen approach offers a strong value proposition supported by groundbreaking neuroscience research. We are positioned to make a significant impact on the treatment of major depressive disorders, bringing relief to all patients, including young people, adolescents and the elderly,' said Delphine Charvin, Chief Executive Officer and Co-Founder of Elkedonia, previously Operating Partner at Argobio. 'In addition, our development of biomarkers will allow us to pursue a precision medicine for patient selection and treatment efficacy monitoring.' *** Notes to EditorsAbout Angelini Ventures Angelini Ventures, the venture capital arm of Angelini Industries, is a Series A and Series B investment firm focused on accelerating disruptive innovations and trends in BioTech and Digital Health. Angelini Ventures will invest €300 million across a global portfolio in Europe and North America, drawing on a global team, strategic advisors and partners to help entrepreneurs scale their businesses into transformative category-leading companies. To date, Angelini Ventures has invested around €100 million into 21 companies covering a range of therapeutic areas and modalities. Angelini Ventures' BioTech portfolio includes Therini Bio, Nuevocor, Neumirna, Cour Pharmaceuticals, Nouscom, Pretzel Therapeutics and Freya Biosciences. The Company's Digital Health portfolio includes Vantis Health, Avation, Cadence Neuroscience, Nobi, Noctrix and Serenis. About Angelini Industries Angelini Industries is a multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over two billion euros, generated in the health, industrial technology and consumer goods sectors. A targeted investment strategy for growth, constant commitment to research and development, deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it About Elkedonia Elkedonia is a Franco-Belgian start-up company dedicated to transforming the treatment of mental health disorders. Elkedonia is introducing a first-in-class antidepressant approach that leverages precision medicine. The lead discovery program targets the inhibition of the intracellular Elk1 protein to address the needs of treatment-resistant depression (TRD). About ArgobioArgobio is an international biotech start-up studio committed to turning cutting-edge innovations into breakthrough biotech companies. The studio sources early-stage therapeutic projects from leading European academic research institutions, focusing on rare diseases, neurological disorders, oncology, and immunology. By selecting and incubating these projects, Argobio aims to develop them into fully-fledged biotech companies, advancing them to significant Seed or Series A financing. With a team of highly experienced biotech entrepreneurs, the studio offers extensive expertise in novel drug discovery and ContactsAngelini VenturesMartina Palmese, Communications Media contacts for Italy - SEC Newgate ItaliaDaniele Pinosa, Tel. +39 3357233872Fausta Tagliarini; Tel. +39 3476474513Daniele Murgia; Tel. +39 3384330031 Media contacts outside Italy - MEDiSTRAVA Sylvie Berrebi, Sandi Greenwood, Mark Swallowangeliniventures@

Trump tariffs may remain in effect during appeals process, court rules
Trump tariffs may remain in effect during appeals process, court rules

Yahoo

time2 hours ago

  • Yahoo

Trump tariffs may remain in effect during appeals process, court rules

President Donald Trump's tariffs will remain in effect, for now, a federal appeals court ruled on Tuesday night. The president's 'Liberation Day' tariffs may stay in place during the appeal process while the court considers the legality of the measures. The federal decision temporarily reverses a lower court's ruling that found Trump had overstepped his authority, according to Reuters. The decision applies to broad-based tariffs affecting most U.S. trading partners, as well as targeted duties on imports from Canada, China, and Mexico amid ongoing pressure for them to do more to stop the illegal flow of immigrants and synthetic opioids across the U.S. border, the Associated Press reported. The court has not yet ruled on whether Trump's use of the International Emergency Economic Powers Act (IEEPA) to impose tariffs is lawful, but agreed to pause the lower court's decision while it hears arguments, which are scheduled for July 31. Trump is the first U.S. president to use IEEPA, a 1977 law historically used to impose sanctions on enemies of the U.S., to impose tariffs. Tuesday's ruling follows a May 28 decision by the U.S. Court of International Trade, which held that the Constitution grants Congress — not the president — the power to impose taxes and tariffs. The tariffs have created turbulence for global markets and American businesses, many of which have struggled to adjust supply chains and pricing strategies amid shifting policy. The ruling on Tuesday does not impact tariffs implemented under separate legal frameworks, which include those on steel and aluminum.

Military deployment in L.A. puts Trump's authority to use troops at home in the spotlight
Military deployment in L.A. puts Trump's authority to use troops at home in the spotlight

Yahoo

time3 hours ago

  • Yahoo

Military deployment in L.A. puts Trump's authority to use troops at home in the spotlight

WASHINGTON — President Donald Trump's move to send National Guard troops and Marines to Los Angeles amid unrest over his immigration policies has given new weight to a lingering question: How far can a president go in using the military to quell domestic disturbances? For now, the military has a limited role in Los Angeles, at least on paper, focused on protecting federal buildings and activities. But that hasn't stopped California's Democratic leaders, including Gov. Gavin Newsom, from vehemently objecting to Trump's actions. Trump has not taken the more drastic step of invoking the Insurrection Act, the name given to a series of legal provisions that allows the president, in certain circumstances, to enlist the military to conduct civilian law enforcement activities. But Elizabeth Goiten, an expert on national security at the Brennan Center for Justice, noted that the memorandum Trump issued Saturday authorizing military involvement in support of immigration enforcement makes no reference to Los Angeles, meaning it applies nationwide. "That's just a red alert," she said. "If we have the military being pre-emptively deployed throughout the country to effectively police protests, that is the hallmark of authoritarian rule." Although the military's role may initially be limited to a protective function, Goiten said that could easily be expanded in certain situations to include use of force and detention of protesters even without invoking the Insurrection Act. She pointed to the response of federal agencies under Trump during protests in Portland and Washington, D.C., in 2020. Ilan Wurman, a professor at the University of Minnesota Law School, said that to this point, Trump has acted within existing precedents that allow the president to use the military to assist with the enforcement of federal law. 'Federalizing the National Guard, using regular forces to restore order, is in my view well within the range of prior precedents,' he said. But, Wurman added, any attempt to invoke the Insurrection Act 'would be more problematic.' Generally, using the military to conduct broad law enforcement activities is forbidden under another law, the 1878 Posse Comitatus Act. But that statute contains many loopholes, of which the Insurrection Act is one. The Posse Comitatus Act was enacted at the tail end of the post-Civil War Reconstruction period, erecting a new barrier against military intervention in the South as it moved toward the Jim Crow era. The last time the Insurrection Act was invoked was during the 1992 Los Angeles riots. President George H.W. Bush acted at the request of Tom Bradley, the Democratic mayor of Los Angeles, and Pete Wilson, the state's Republican governor. Previously, the act was used to desegregate schools in the 1950s and '60s amid opposition from state and local leaders in the South. In calling in the National Guard, Trump invoked a different law that allows the president to do so when there is an invasion or a danger of invasion or a rebellion or a danger of rebellion or when "the president is unable to with the regular forces to execute the laws of the United States." The law states that orders 'shall be issued through the governors of the states,' which has not happened in this case, as Newsom is adamantly opposed to Trump's move. California has filed a lawsuit that cites the skirting of Newsom's role under that provision as well as broader claims that Trump is infringing on California's sovereignty, among other things. "There is no invasion. There is no rebellion," California Attorney General Rob Bonta said Monday. In a new court filing Tuesday, Bonta said there was a "substantial likelihood" that troops will "engage in quintessential law enforcement activity" in violation of the Posse Comitatus Act if a judge does not take immediate action. He cited plans for National Guard members to provide support for immigration operations by, for example, securing perimeters in communities where enforcement activities are taking place. NBC News has separately reported that Marines deployed to Los Angeles could be used to transport immigration officers to arrest locations. Attorney General Pam Bondi has said she fully backed Trump's actions. 'We are going to enforce the law regardless of what they do,' she said, referring to Newsom in a Fox News interview Monday. 'Look at it out there. It looks like a Third World country.' Chris Mirasola, a professor at the University of Houston Law Center, said the impact of Trump's current plan could be limited by practical considerations, including the number of military personnel available and the cost of paying National Guard troops on active duty. "This ends up becoming extremely expensive very quickly," he added. The cost of the Los Angeles deployment alone is about $134 million, a defense department official said Tuesday. Military personnel are also likely to have little training in how to approach a domestic protest. "This is not in their normal mission set. There's always risk of escalation," which would only be more pronounced if the Insurrection Act was used, Mirasola added. If the president invokes the Insurrection Act, troops would not be limited by law to protecting federal property and personnel. Instead, they could have a much more active role on the streets, with a greater possibility of encountering civilians. While troops may not be able to carry out all the functions of federal law enforcement officers, such as conducting immigration raids, they could assist without violating the law, Mirasola said. There are also questions about whether the judiciary would intervene if Trump sought to use the Insurrection Act — or even who would have legal standing to sue to stop Trump. Litigation in that scenario could mirror a legal fight that has already played out over the Trump administration's efforts to use a wartime law, the Alien Enemies Act, to swiftly deport certain immigrants without affording them due process. The Supreme Court said due process is required, that detainees be given a proper chance to raise legal objections before a federal judge. But the court also said such lawsuits must be brought via habeas corpus claims from the people affected, not under a federal law called the Administrative Procedure Act. Any attempt to use the Insurrection Act could be challenged, 'but what shape the challenge takes may depend on the basis for invocation, how it is implemented and how it is directly carried out on the ground,' a civil rights lawyer said. Although Trump and his allies have referred to protesters in Los Angeles as "insurrectionists," there is no plan at the moment to invoke the Insurrection Act, a White House official told NBC News. Speaking on Sunday about whether he would seek to use the law, Trump said there was not currently a reason to but did not rule it out in future. 'Depends on whether or not there's an insurrection," he said. This article was originally published on

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store